• Home
  • Prestige Biopharma Limited
6
Oct
2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
stand 5D114
Book a meeting

Prestige Biopharma Limited

About Prestige Biopharma Limited

Prestige Biopharma is a global antibody-focused biopharmaceutical company advancing a diversified portfolio of commercial-stage biosimilars, first-in-class therapeutics and proprietary platform technologies. Our biosimilar portfolio is led by EU-approved Tuznue™ (trastuzumab biosimilar), alongside a late-stage pipeline including bevacizumab and adalimumab biosimilars. Our innovative pipeline features Ulenistamab (PBP1510), a first-in-class antibody for pancreatic cancer in clinical stage, and PBP1710, a preclinical-stage antibody targeting oncology and fibrosis. Complementing these assets are proprietary platforms - TASA™ for early cancer detection and a subcutaneous hydrogel platform.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI Milan 2026

    CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
    stand 5D114
  • Country/Region:
    Singapore
  • On CPHI since:
    2018
  • Employees:
    250 - 499
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
Contact info
Show contact info Hide contact info

Products from Prestige Biopharma Limited (4)

  • Tuznue™ (Trastuzumab biosimilar)

    Product Tuznue™ (Trastuzumab biosimilar)

    Tuznue™ is a biosimilar of Herceptin® (trastuzumab), developed to offer a more cost-effective therapeutic alternative for patients. It maintains comparable efficacy and safety profiles to the original branded medication. Tuznue™ is indicated for the treatment of patients with HER2-positive metastatic breas...
  • HD204 (Bevacizumab biosimilar)

    Product HD204 (Bevacizumab biosimilar)

    This is a biosimilar candidate of bevacizumab (Avastin®). Bevacizumab is used to treat many different types of cancer (often as first-line therapy) including metastatic colorectal cancer, non-small-cell lung cancer (NSCLC), renal cell cancer, ovarian cancer and metastatic breast cancer. Global Phase 3 ...
  • PBP1502 (Adalimumab biosimilar)

    Product PBP1502 (Adalimumab biosimilar)

    This is a biosimilar candidate of adalimumab (Humira®). Adalimumab is used to treat many inflammatory conditions in adults, such as rheumatoid arthritis. Phase 1 IND approved in Spain and the study is currently ongoing.

  • PBP1510 (INN: Ulenistamab)

    Product PBP1510 (INN: Ulenistamab)

    PBP1510 is a first-in-class monoclonal antibody drug developed by Prestige Biopharma Limited against pancreatic adenocarcinoma up-regulated factor (PAUF), a protein that is overexpressed in pancreatic adenocarcinoma. PAUF is involved in promoting tumor growth, invasion, and metastasis, in the evasion o...